Physician profile
Frank Freund
NPI 1609304872
$1,383.73
in general payments reported to CMS, 2019-2025
18 companies · $136 in 2025
The $136 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $554 · 2020: $159 · 2021: $12.34 · 2022: $251 · 2023: $45.78 · 2024: $226 · 2025: $136.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $408.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $407.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $237.50 | 2019-2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $220.58 | 2022-2025 | Lifevest |
| Abbvie INC. | $172.25 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $146.03 | 2019-2025 | Jardiance |
| Vifor Pharma, INC. | $121.84 | 2019 | |
| Janssen Pharmaceuticals, INC | $107.87 | 2022-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $78.51 | 2022-2024 | Lokelma |
| Pfizer INC. | $71.25 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $41.11 | 2022-2024 | Dificid, Zerbaxa, Recarbrio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.40 | 2020 | |
| Shire North American Group INC | $27.75 | 2019 | |
| Novartis Pharmaceuticals Corporation | $24.91 | 2021-2022 | |
| Kestra Medical Technology Services, INC. | $23.99 | 2022 | |
| Edwards Lifesciences Corporation | $23.37 | 2024 | Sapien 3 Ultra Resilia |
| Ironwood Pharmaceuticals, INC | $15.87 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $15.04 | 2019 | |
| Eisai INC. | $13.42 | 2019 | |
| Arbor Pharmaceuticals, INC. | $13.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frank Freund listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.